Recent updates and news regarding
WSI PBG
Be sure to check back frequently to keep up to date on the happenings at WSI PBG.
Looking for the most recent updates for WSI PBG LLC?
For the most recent updates, go to our LinkedIn page!
August 1, 2024
GSMS Acquisition of WSI PBG: A Strategic Move Toward Growth
Camarillo, CA – August 1, 2024 – Golden State Medical Supply, Inc. (“GSMS”), the leading provider of pharmaceuticals to the federal healthcare systems, is pleased to announce the acquisition of WSI PBG, LLC (“WSI”), the first and only contract sales organization that specializes in addressing the federal healthcare market. This strategic acquisition is set to enhance GSMS’s capabilities and expand its market presence in the federal healthcare sector.
Key Highlights of the Acquisition:
· Innovation and Growth: This acquisition aligns with GSMS’s commitment to innovation and growth, providing new opportunities for development and expansion.
· Market Expansion: With the integration of WSI’s resources and customer base GSMS will strengthen its expansion from its successful generic pharmaceutical core.
· Enhanced Capabilities: The acquisition of WSI will bring an exquisite team of professionals and a unique service model, enabling both organizations to collaborate and deliver a more comprehensive suite of services to the industry’s pharmaceutical and medical device manufacturers.
About GSMS:
Golden State Medical Supply, Inc. (GSMS) is a pharmaceutical company based in Camarillo, California. They specialize in providing a wide range of pharmaceutical products, focusing on improving health and the quality of care for patients. GSMS primarily services the U.S. Federal Healthcare system, including the Department of Veterans Affairs (VA) and the Department of Defense (DoD). They offer a large portfolio of prescription products across various dosage forms.
About WSI PBG, LLC:
WSI PBG, LLC (“WSI”), a privately held, Michigan-based company that specializes in federal market access and sales. WSI has the largest Federal Account Management group driving access and sales pull-through for pharmaceuticals, biologics, medical equipment & devices, services, vaccines and diagnostics.
January 1, 2024
WSI has extended and expanded the partnership with Sanofi Immunology effective January 1, 2024
WSI has contracted with Averitas to promote Qutenza within the Federal Markets
WSI has extended and expanded the partnership and product portfolio with Supernus
WSI will represent Rayaldee for Secondary Hyperparathyroidism in patients with CKD on behalf of Opko Health, Inc
WSI is a “Founding Partner” for the Association of VA Neurology Services (AVANS). First annual meeting is scheduled in February 2024.
September 1, 2023
WSI kicked off its second agreement with Sanofi to create a Federal Account Management team which will represent Sarclisa within the Federal Markets.
August 18, 2023
WSI entered into a consulting agreement with Collegium Pharmaceuticals, Inc.
June 15, 2023
WSI developed and initiated the execution of federal sales training for Amgen and Taiho Key Account Management teams.
June 1, 2023
WSI entered a long-term partnership with Paratek Pharmaceuticals, Inc. to represent Nuzyra for appropriately indicated infections to Infectious Disease and Critical Care providers within the VA and Military Healthcare Systems.
May 1, 2023
WSI awarded contract extension with Karyopharm
April 17,2023
Federal field team finalized to begin promoting Doptelet within the VA Healthcare System on behalf of Sobi Pharmaceuticals
April 1, 2023
WSI entered into an agreement with eNeura to launch SAVI Dual for the treatment and prevention of Migraines within the Federal Healthcare systems
February 15, 2023
Halozyme / Antares approves the contract extension to have WSI promote Xyosted as a treatment option for TRT within MTF and VA facilities.
February 2, 2023
Agreement to represent Dupixent within the military and VA HCSs was executed by and between WSI and Sanofi.
February 1, 2023
WSI Federal Team expands to 45 individuals including 37 full time field based Federal Account Managers (FAMs).
February 2, 2023
Negotiating with eNeura to promote SAVI Dual for Military and Veteran beneficiaries suffering from Migraine.
January 1, 2023
Merck approves an additional headcount to the WSI VA Oncology Key Account Management Team.
December 15, 2022
Amylyx agrees to extend consulting service with WSI centered around VA Neurology service and ALS.
October 24, 2022
Entered agreement with Amryt Pharmaceuticals to introduce Mycapssa within the Federal markets.
October 15, 2022
Col Markus Gmehlin (Ret) joined the WSI Leadership team as a National Federal Business Director. Prior to joining WSI, Markus served as the global Pharmacy Operations Director at Defense Health Agency.
October 1, 2022
WSI initiated federal sales contract with Acadia to promote Nuplazid for Parkinson’s disease associated psychosis.
September 18, 2022
WSI celebrates its 4 year anniversary as the Federal Promotional partner representing Lenvima on behalf of Eisai.
September 11, 2022
WSI celebrates its 3 year anniversary as the Federal Promotional partner representing the Exelan generic product portfolio within the federal markets.
September 1, 2022
WSI enters into its second contract with the Janssen Biotech Oncology franchise to promote brands indicated for patients with prostate cancer and NSCLC with EGFR exon 20 mutations.
August 1, 2022
Mark Walton, RPh, MS joined the WSI Leadership team as a National Federal Business Director. Prior to joining WSI, Mark served in the VA in multiple pharmacy operations and leadership positions, including being recognized as the first VISN Pharmacy Executive in VISN 8. Following his service within the VA, Mark developed extensive industry pharmaceutical, diagnostic and medical supply sales and contracting experience.
February 28, 2022
WSI FAM Team successfully completes Turalio training under new agreement with Daiichi Sankyo.
January 25, 2022
Foundation Medicine has approved leveraging WSI consulting services specifically relating to the Military Health Laboratory Services.
January 21, 2022
WSI will be attending the Society of Government Service Urologists (SGSU) next week representing multiple client urology product portfolios including QBioMed product Strontium 89 which can be used for relief of bone pain in patients with bone metastases.
January 17, 2022
WSI becomes the FIRST AMSUS-SM Small Company Member to receive the Tip of The Spear Award which is presented to companies who exemplify service to country by advancing federal health, while embracing public/private partnership with Federal Health agencies and leaders.
January 14, 2022
WSI CEO, Richard Ryan, is pleased to announce that WSI has entered into a Master Service Agreement (MSA) with Karyopharm Therapeutics with the intent to support the promotion of their Oncology product line.
December 31, 2021
WSI has finalized an extended agreement to launch MedLite ID within the Federal Healthcare Systems. MedLite ID is an easy-to-use, disposable medical device that enables clinicians to accurately and efficiently identify the single medication infusion line for IV drug administration.
December 24, 2021
WSI has finalized an extended agreement to launch MedLite ID WSI VP of federal Sales, Tammy Pritchard, is excited to announce the expansion of the WSI Federal Sales and Account Management team which will add an additional 7 regions to the WSI federal field team.
December 17, 2021
Effective January 1, 2022 WSI will begin to support the awareness and value proposition for the Petros Pharmaceutical Erectile Dysfunction (ED) product portfolio which will include Stendra (avanafil tablets).
December 10, 2021
Antares Pharmaceuticals and WSI will partner to promote XYOSTED (weekly testosterone auto injector therapy) within the VA and Military healthcare systems effective January 1, 2022.
December 3, 2021
CEO, Richard Ryan, is honored to announce that WSI VA Key Account Managers will continue to represent Keytruda on behalf of Merck within the VA Healthcare System in 2022.
